Pharma Business – July 7, 2025
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).
Biotech Award – July 2, 2025
BioArctic’s founder, Professor Lars Lannfelt, will receive the prize for his pioneering contributions to the understanding of Alzheimer’s disease and to the development of the drug lecanemab.
Agreement – July 2, 2025
The companies have entered into a supply and commercialization agreement for AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).
New Market – July 2, 2025
Camurus has announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Biotech Business – July 2, 2025
The company has been awarded grant and equity financing from the European Innovation Council (EIC) Accelerator, a funding initiative under the European Union’s Horizon Europe program designed to support highly innovative start-ups with disruptive technologies.
Science Award – June 29, 2025
Doctor Maximilian Ackermann, currently working as a Professor of Pathology at the RWTH University Clinics Aachen and Helios University Hospital Wuppertal, Germany, and as anatomist at the Johannes Gutenberg University Mainz is awarded the 2025 Lennart Nilsson Award for his outstanding contributions to scientific imaging, revealing critical insights into diseases, such as COVID-19 and cancer.
Clinical Trials – June 19, 2025
The interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated.
Clinical Trials – June 18, 2025
The company has announced results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer.
Clinical Trials – June 18, 2025
The company has presented results from a recently completed study that further demonstrates the potential of its vaccine platform for pandemic preparedness.
Clinical Trials – June 10, 2025
The phase 2a proof-of-concept DELTA NEXT trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP).
Clinical Trials – June 4, 2025
LINK Medical has been engaged to conduct a feasibility study in Europe for the company’s planned Phase 3 study for European approval of BupiZenge.
Clinical Trials – May 26, 2025
Preliminary principal investigator-assessed outcomes from the first patient cohort in the ongoing Phase I/IIa CARMA study with ELC-301 show that two out of three treated patients had no active lymphoma detected on specialized scans, achieving a complete metabolic response.
Collaboration – June 25, 2025
The two companies will explore OXC-101 in topical formulations for medical dermatology indications including psoriasis.
Pharma Business – June 24, 2025
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial. STRIDE is the only dedicated PAD functional outcomes trial with a glucagon-like peptide-1 receptor […]
Global report – June 13, 2025
AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.
Financing – June 25, 2025
Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
Acquisition – June 25, 2025
MedCap’s wholly owned subsidiary, Unimedic Pharma, has signed an agreement to acquire XGX Pharma in Denmark.
Finland – June 24, 2025
The new factory in Turku will enable up to ten times the production capacity.
Biotech Business – June 25, 2025
Evaxion initiates work to develop a new preventive vaccine against Group A Streptococcus (GAS).
Biotech Business – June 25, 2025
The aim of the project is to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.
Biotech Business – June 24, 2025
Cereno Scientific has announced entering loan financing agreements.
Science article – June 4, 2025
All over the world, countries are experiencing a demographic shift towards aging populations. The field of aging research seeks to answer the question of how we can age healthier, and not just live longer.
Science News – May 25, 2025
The study suggests that reduced mitochondrial metabolism can contribute to body fat accumulation and diminished insulin sensitivity which can, in turn, trigger chemical DNA modifications that alter gene regulation.
Collaboration – May 21, 2025
The project “Validated non-invasive liquid biopsy tests for cancer PREDIction in LYNCH Syndrome, PREDI-LYNCH” is funded by the European Commission Horizon Europe Mission on Cancer.
Stryker
In this position, you oversee your region and businesses, in various stages of development both with a high potential and focus, driving revenue and further developing the Flanders region.
Stryker
Take charge of sales activities for our Upper Extremities portfolio, including shoulder arthroplasty, fracture fixation, and other advanced surgical solutions.
Stryker
As a Sales Representative in our Surgical Technologies division, you’ll play a critical role in helping hospitals and surgical teams deliver exceptional care.
Stryker
This is a high-impact position within the Netherlands Sales team and an excellent next step in your sales career.
Stryker
You’ll be part of a high-performing, collaborative team in a fast-paced and purpose-driven environment where innovation and personal growth are valued.
Stryker
As the new Sales Representative Neurosurgical & ENT, you will help us deliver on our mission of making healthcare better by promoting and selling Stryker’s Neurosurgical and ENT (Ear, Nose & Throat) products, covering the Flanders region of Belgium.
In a new job – June 12, 2025
The board of SyntheticMR has appointed Lena Åredal as the new CEO.
In a new job – June 11, 2025
Malin Walfridsson, former Head of R&D at Nordic Biomarker, has joined the company as COO and Deputy CEO.
In a new job – June 9, 2025
The company has appointed Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.
Careers article – June 13, 2025
Despite international turbulence and news of life sciences and research funding disruptions in the U.S., investment in innovative life sciences projects continues, according to Mala Valroy, an investment manager with Industrifonden, one of Sweden’s largest evergreen venture capital (VC) funds.
Careers article – June 11, 2025
25 new researchers from all over the world will hopefully arrive in Lund this autumn.
Biotech Business – May 27, 2025
The planned restructuring would result in an approximately 20% reduction in the current workforce.
Profiles in Pharma – April 2, 2025
For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.
Nobel Prize Laureate – December 12, 2024
Victor Ambros, Professor of Molecular Medicine and the Silverman Chair in Natural Sciences at the University of Massachusetts Chan Medical School, is one of this year’s winners of the Nobel Prize in Physiology or Medicine.
Nobel Prize Laureate – December 10, 2024
More than three decades after their discovery of microRNA, Professor Gary Ruvkun received the “mythic call” from Stockholm to learn that he’d been awarded the Nobel Prize in Physiology or Medicine alongside his erstwhile colleague Victor Ambros.
This site uses cookies
